Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.

These trials have shown little therapeutic benefit to the patients enrolled[ 19 ] , with the exception of a combination of erlotinib and gemcitabine, which shows only a marginally significant benefit.[ 93 ] Therefore, identification of new molecular target(s) as well as approach for modulation of tumor microenvironment (eg, tumor stroma,[ 12 13 94 ] tumor-associated inflammation[ 65 66 ] ) is necessary for developing therapeutic strategies that enhance the effect of gemcitabine and improve patient survival.

also in 26,082 other papers